AT 720
Alternative Names: AT-720Latest Information Update: 28 Feb 2023
At a glance
- Originator Audentes Therapeutics
- Developer Astellas Gene Therapies
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neuromuscular disorders
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for research development in Neuromuscular-disorders in USA (Parenteral)
- 01 Apr 2021 Audentes Therapeutics is now called Astellas Gene Therapies
- 15 Jan 2020 Audentes Therapeutics has been acquired by Astellas Pharma